TAKEDA PHARMACEUTICAL CO LTD business relationships

“*1 Partnership with Pfizer Inc.” SEC filing

“During the fiscal year ended March 31, 2025, Takeda decided to enter into discussions with Teva Pharmaceutical Industries Ltd. to dissolve a joint venture business in Japan primarily focused on generic medicines and long-listed products.” SEC filing

“The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 579,065 million, JPY 578,767 million and JPY 436,951 million, respectively, for the year ended March 31, 2024.” SEC filing

“The sales to McKesson Group and Cencora Group were JPY 592,323 million, JPY 577,017 million, respectively, for the year ended March 31, 2025.” SEC filing

“| Exelixis | | U.S. | | Exclusive licensing agreement to commercialize and develop CABOMETYX (cabozantinib) and its all potential future indications in Japan, including advanced renal cell carcinoma and hepatocellular carcinoma. |” SEC filing

“| Denali Therapeutics | | U.S. | | Strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases, incorporating Denali's transport vehicle (TV) platform for increased exposure of biotherapeutic products i...” SEC filing

“She also helped establish strategic partnerships with Moderna and Novavax and supported the collaboration with the Government of Japan to secure COVID-19 vaccine supply during the pandemic.” SEC filing

“| Neurocrine Biosciences | | U.S. | | Collaboration to develop and commercialize 7 compounds in Takeda's early-to-mid stage neuroscience pipeline, including TAK-041/NBI-1065846, TAK-653/NBI-1065845 and TAK-831/NBI-1065844 (luvadaxistat).” SEC filing

“In the fiscal year ended March 31, 2026, there were two wholesale distributors, McKesson Group and Cencora Group, that each individually accounted for over ten percent of Takeda's total revenue.” SEC filing

“In the fiscal year ended March 31, 2026, there were two wholesale distributors, McKesson Group and Cencora Group, that each individually accounted for over ten percent of Takeda's total revenue.” SEC filing

“...ocess as the standard half-life recombinant factor VIII therapy ADVATE, and adds a proven technology, PEGylation (a chemical process that prolongs the amount of time a compound remains in circulation, potentially allowing for fewer injections), which we exclusively licensed from Nektar Therapeutics.” SEC filing

“| Mirum Pharmaceuticals | | U.S. | | Exclusive licensing agreement for the development and commercialization of LIVMARLI (maralixibat, TAK-625) in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). |” SEC filing

“*3 Partnership with Protagonist Therapeutics.” SEC filing

“The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 579,065 million, JPY 578,767 million and JPY 436,951 million, respectively, for the year ended March 31, 2024.” SEC filing

“| AbbVie | | U.S. | | Exclusive licensing agreement to develop and commercialize mirvetuximab soravtansine-gynx in Japan for folate receptor-alpha (FRa) positive ovarian cancer. |” SEC filing

“*4 Partnership with AbbVie.” SEC filing

“The corrective actions resulted in a temporary supply shortage of Leuprorelin, a product which we supply to AbbVie, Inc. ("AbbVie") pursuant to a supply agreement.” SEC filing

“*3 Partnership with Arrowhead Pharmaceuticals” SEC filing

“*7 Partnership with Kumquat Biosciences Inc. Kumquat leads P-I development.” SEC filing

“In December 2024, Takeda entered into an exclusive licensing agreement with Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.” SEC filing

“*5 Partnership with Keros Therapeutics, Inc.” SEC filing

“*6 Partnership with Innovent Biologics.” SEC filing

“In the Asia Pacific region, we also sell our products in partnership with other companies, including Astellas Pharma Inc., BeOne, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd. and Kyowa Kirin.” SEC filing

“(4) Adcetris is commercialized in collaboration with Takeda.” SEC filing

“As a result, REC-4881 was in-licensed from Takeda and subsequently advanced into preclinical studies.” SEC filing

“During a collaboration with Takeda, we leveraged machine learning and automated analysis to quantify hundreds of cellular parameters linked to APC siRNA knockdown.” SEC filing

“In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. ("Takeda"), for the research, development, manufacture and commercialization of ATTENUKINE” SEC filing

“...rapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Therapeutics, Inc., Silence Therapeutics plc, Takeda Pharmaceutical Company Ltd., and Wave Life Sciences Ltd., as well as our collaborators Regeneron, Roche, Sanofi and Vir.” SEC filing

“...ncial terms to replace the share of operating profits and, instead, provide us with a tiered royalty as a percentage of Takeda's, its affiliates' and sublicensees' total net sales in the mid to high-teen percentages (subject to certain capped royalty reductions), which commenced on April 1, 2024 and...” SEC filing

“...ncial terms to replace the share of operating profits and, instead, provide us with a tiered royalty as a percentage of Takeda's, its affiliates' and sublicensees' total net sales in the mid to high-teen percentages (subject to certain capped royalty reductions), which commenced on April 1, 2024 and...” SEC filing

“In April 2025, the Company entered into a collaboration and exclusive license agreement, as amended ("Amended Takeda CLA"), with Takeda which amended and superseded its collaboration and exclusive license agreement with Takeda, dated February 24, 2021 ("Original Takeda CLA").” SEC filing

“...tinuing during the term of the Sanofi CLA, we and Sanofi will commercialize the COVID-19 Vaccine worldwide in accordance with a commercialization plan agreed by the parties, under which we will continue to supply certain of our existing APA customers and strategic partners, including Takeda and SII.” SEC filing

“The Takeda Support Services provide a distinct benefit to Takeda within the context of the contract, separate from the license, as the services could be provided by Takeda or another third party without the Company's assistance.” SEC filing

“The Company also believes that Takeda meets the definition of a customer as defined in ASC 606, Revenue From Contracts With Customers for the PTV:PGRN Technology License performance obligation delivered in the collaboration agreement.” SEC filing

“We and Takeda may each terminate the Takeda Collaboration Agreement in its entirety if the other party is declared insolvent or in similar financial distress or if, subject to a specified cure period, the other party challenges any patents licensed to it under the Takeda Collaboration Agreement.” SEC filing

“We have an active collaboration with Takeda Pharmaceutical Company Limited ("Takeda") for the development and commercialization of TAK-594/DNL593 (PTV:PGRN) for FTD- GRN .” SEC filing

“Outside the U.S. and Japan, cabozantinib is licensed to Ipsen, and in Japan, cabozantinib is licensed to Takeda, each in accordance with the respective collaboration agreements.” SEC filing

“In January 2017, we entered into a collaboration and license agreement with Takeda, as subsequently amended to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as...” SEC filing

“....S., we continued to work closely with our collaboration partner Ipsen in support of its regulatory strategy and commercialization efforts for CABOMETYX, both as a single agent and in combination with nivolumab, and similarly with our collaboration partner Takeda with respect to the Japanese market.” SEC filing

“In addition, we rely on Ipsen and Takeda for ongoing and further commercialization and distribution of CABOMETYX in territories outside of the U.S., as well as for access and distribution activities for the approved products, including named patient use programs or similar programs, and we also rely...” SEC filing

“We currently earn royalties from the sales of ten commercial products including sales of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.” SEC filing

“Additionally, we are entitled to receive royalties from Takeda on the future net sales of osavampator in Japan.” SEC filing

“Osavampator was in-licensed from Takeda Pharmaceutical Company Limited (Takeda) in 2020, and we have exclusive worldwide rights to develop and commercialize osavampator, except in Japan, where Takeda has exclusive development and commercialization rights.” SEC filing

“Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” SEC filing

“| | ● | | iPSC-based assay developments : Fate Therapeutics, Allele Biotechnology, Takeda, and Fujifilm, along with Contract Manufacturing Organizations ("CMOs") such as Lonza, SCM Lifescience, Reporcell and Charles River Laboratories. |” SEC filing

“Revenue from Baxalta (a subsidiary of Takeda Pharmaceutical Company Limited), AstraZeneca, and UCB represented 45 %, 37 %, and 14 % of our revenue, respectively, for the year ended December 31, 2025 .” SEC filing

“ACI-24.060 is the subject of an exclusive option and license agreement with Takeda.” SEC filing

“...t gains and losses that arise from our cash being held in currency other than Swiss Francs, certain collaboration agreements such as the collaboration agreements with LMI or Takeda being denominated in currencies other than Swiss Francs, and selected purchases, which we effect in foreign currencies.” SEC filing

“are in the United States (by Takeda) and, commencing in 2024, GLASSIA is also being sold by Takeda in Canada, through our companies'” SEC filing

“largest customers, Kedrion, Takeda and Clalit Health Services accounted for 23%, 11% and 7%, respectively, of our total revenues.” SEC filing

“the end of 2023, GLASSIA was distributed by Takeda only in the United States and, commencing in 2024, also in Canada); (2) a technology” SEC filing

“Commencing 2022, the Company collected royalty payments from Takeda” SEC filing

“Pursuant to our licensing agreement with Takeda, we are entitled to a guaranteed minimum of” SEC filing

“Takeda, our strategic partner for sales of GLASSIA” SEC filing

“In addition, we rely on Takeda,” SEC filing

“• Gene Silencing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnylam Pharmaceuticals, Inc.), which are developing interfering RNA medicines to treat the liver manifestat...” SEC filing

“We expect that total product sales of our approved medicines will continue to increase on an annual basis; however, due to large periodic orders from Takeda and our distributors, our product revenue may experience quarterly fluctuations.” SEC filing

“Licensing Agreement with Takeda” SEC filing

“Under the RLT Agreement, all rights in soticlestat are owned by Takeda or exclusively licensed to Takeda by the Company.” SEC filing

“In January 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.” SEC filing

“In January 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.” SEC filing

“Pursuant to our exclusive license agreement with Takeda, we are responsible for global development and commercialization of alisertib.” SEC filing

“While our drug candidates were developed by Pfizer and Takeda, both the drug substance and drug product are manufactured by third-party contractors.” SEC filing

“For the year ended December 31, 2025, Takeda accounted for 100 % of the Company's revenues.” SEC filing

“In addition, the Company is eligible to receive additional worldwide development, regulatory and commercial milestone payments for rusfertide of up to $ 305.0 million, and tiered royalties from 10 % to 17 % on net sales of the Licensed Products in the Takeda Territory.” SEC filing

“We do not maintain significant rights or control of future development and commercialization activities under our collaboration with JNJ, or in ex-U.S. territories under our collaboration with Takeda.” SEC filing

“| | ● | | We rely on Takeda Pharmaceuticals USA, Inc. ("Takeda") to successfully commercialize rusfertide. |” SEC filing

“In February 2018, the Company entered into a global strategic collaboration with Takeda Pharmaceutical Company Limited ("Takeda"), pursuant to which the Company agreed to collaborate with Takeda on the research, development and commercialization of oligonucleotide therapeutics for disorders of the c...” SEC filing

“Revenue relating to the functional licenses provided to Takeda was recognized at a point in time when the control of the license transferred to the customer.” SEC filing

“Takeda Strategic Collaboration and License Agreement” SEC filing

“In addition, in June 2024, we issued and sold to Takeda 24,307,322 ordinary shares, or the Takeda Shares, for an aggregate” SEC filing

“to Takeda an exclusive option to enter into an exclusive license agreement, under which Takeda would have the exclusive right (even as” SEC filing

“Takeda may terminate the Takeda License Agreement if we challenge a licensed patent.” SEC filing

“Royalty income on sales of Alofisel ® by our licensee Takeda decreased by $0.1 million in the year ended June 30, 2026 compared with the year ended June 30, 2025.” SEC filing

“No milestone revenue was recognized in the years ended June 30, 2026, 2025 and 2024 in relation to the Group's patent license agreement with Takeda.” SEC filing

“In addition, we are required to make milestone and royalty payments to Takeda, from whom we have in-licensed the rights to develop and commercialize vonoprazan in the United States, Europe, and Canada pursuant to the Takeda License, and we have ongoing financial obligations under our Loan Agreement...” SEC filing

“Our patent portfolio covering vonoprazan consists predominantly of patents and patent applications that are exclusively licensed to us from Takeda pursuant to the license agreement we entered into on May 7, 2019, or the Takeda License.” SEC filing

“We plan to rely, in part, on third parties, including Takeda and any future collaborators, vendors or contract research organizations, to comply with these adverse event reporting requirements.” SEC filing

“We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada.” SEC filing

“On March 7, 2024, we entered into a Settlement Agreement (the "Settlement Agreement") with Takeda to resolve the action and entered into a license agreement with Takeda pursuant to which Takeda granted a non-exclusive license to us and our affiliates of certain patents owned by Takeda.” SEC filing

“For example, we were party to collaboration agreements with Takeda Pharmaceutical Company, Ltd.("Takeda")and Ono Pharmaceutical Company, Ltd. ("Ono"), which were terminated, and will not receive any future funding under those agreements.” SEC filing

“The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023.” SEC filing

“Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen, Horizon, GSK, Sarepta, Visirna and Novartis Pharma AG ("Novartis").” SEC filing

“Denali Therapeutics Inc., in partnership with Takeda Pharmaceutical Company Limited, is conducting a Phase 1/2 clinical trial for their recombinant progranulin protein.” SEC filing

“License Agreement by and among Takeda Pharmaceuticals International AG, HUTCHMED (China) Limited and HUTCHMED Limited dated as of January 23, 2023 (incorporated by reference to Exhibit 4.16 to our annual report on Form 20 - F filed with the SEC on February 28, 2023)” SEC filing

“Fruquintinib is marketed as Elunate in China by HUTCHMED, and as Fruzaqla outside of China by our partner Takeda.” SEC filing

“For Fruzaqla, Elunate and Orpathys, they represent total sales to third parties as provided by Takeda, Eli Lilly and AstraZeneca, respectively.” SEC filing

“License agreement with Takeda signed in 2023” SEC filing

“2024 License Agreement with Takeda Pharmaceuticals U.S.A., Inc.” SEC filing

“activities under our collaboration with Takeda.” SEC filing